Lymphomas

Common Treatments

 

Commonly Used Medications for Hodgkin Lymphoma

Chemotherapy
bleomycin (Blenoxane)
cyclophosphamide
dacarbazine (DTIC-Dome)
doxorubicin hydrochloride (Adriamycin)
mechlorethamine (Mustargen)
procarbazine (Matulane)
vinblastine (Velban)
vincristine (Oncovin)
Corticosteroid
prednisone
Immunotherapy
nivolumab (Opdivo)
pembrolizumab (Keytruda)
Targeted Therapy
Monoclonal Antibody
brentuximab vedotin (Adcetris)
Some Possible Combinations
ABVD: doxorubicin (Adriamycin), bleomycin (Blenoxane), vinblastine (Velban) and dacarbazine (DTIC-Dome)
ABVD + R: doxorubicin (Adriamycin), bleomycin (Blenoxane), vinblastine (Velban), dacarbazine (DTIC-Dome) and rituximab (Rituxan)
BEACOPP: bleomycin (Blenoxane), etoposide (Etopophos), doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine (Matulane) and prednisone
ChlVPP: chlorambucil (Leukeran), vinblastine (Velban), procarbazine (Matulane) and prednisone
ICE: ifosfamide, carboplatin and etoposide
Stanford V: doxorubicin (Adriamycin), mechlorethamine (Mustargen), vincristine (Oncovin), bleomycin (Blenoxane), etoposide (Etopophos) and prednisone

As of 5/7/20

 

Commonly Used Medications for Non-Hodgkin Lymphoma

Chemotherapy
bendamustine (Bendeka, Treanda)
carboplatin
chlorambucil (Leukeran)
cisplatin
cyclophosphamide
doxorubicin hydrochloride (Adriamycin)
fludarabine (Fludara)
methotrexate
procarbazine (Matulane)
vincristine (Oncovin)
Corticosteroids
dexamethasone
methylprednisolone
prednisone
Immunotherapy
CAR T-Cell Therapies
axicabtagene ciloleucel (Yescarta)
tisagenlecleucel (Kymriah)
Immune Checkpoint Inhibitor
pembrolizumab (Keytruda)
Immunomodulator Therapy
lenalidomide (Revlimid)
Radioimmunotherapy
ibritumomab (Zevalin)
Targeted Therapy
BCL-2 Inhibitor
venetoclax (Venclexta)
Kinase Inhibitors
acalabrutinib (Calquence)
copanlisib (Aliqopa)
duvelisib (Copiktra)
ibrutinib (Imbruvica)
idelalisib (Zydelig)
zanubrutinib (Brukinsa)
Monoclonal Antibodies
brentuximab (Adcetris)
mogamulizumab-kpkc (Poteligeo)
obinutuzumab (Gazyva)
polatuzumab vedotin-piiq (Polivy)
rituximab (Rituxan)
rituximab and hyaluronidase human (Rituxan Hycela)
rituximab-abbs (Truxima)
rituximab-pvvr (Ruxience)
Proteasome Inhibitor
bortezomib (Velcade)
Some Possible Combinations
BR: bendamustine (Bendeka, Treanda) and rituximab (Rituxan)
CHOP: cyclophosphamide, doxorubicin (Adriamycin), vincristine (Oncovin) and prednisone
CODOX-M/IVAC: cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin) and intrathecal methotrexate, and cytarabine followed by high-dose systemic methotrexate and rituximab (Rituxan)
CVP: cyclophosphamide, vincristine (Oncovin) and prednisone
EPOCH-R: etoposide (Etopophos), prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin (Adriamycin) and rituximab (Rituxan)
Hyper-CVAD: cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin) and dexamethasone, alternating with high-dose methotrexate plus cytarabine and rituximab (Rituxan)
P+BR: polatuzumab (Polivy), bendamustine (Bendeka, Treanda) and rituximab (Rituxan)
R-CHOP: rituximab (Rituxan), cyclophosphamide, doxorubicin (Adriamycin), vincristine (Oncovin) and prednisone
R-CVP: rituximab (Rituxan), cyclophosphamide, vincristine (Oncovin) and prednisone

As of 5/7/20

 

Previous Next

 



Register Now! Sign Up For Our Free E-Newletter!

Read Inspiring Cancer Survivor Stories

Order Your Guides Here